SBL
GRCE

Sargent Bickham Lagudis’s Grace Therapeutics GRCE Stock Holding History

Sargent Bickham Lagudis’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 1032
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1026
2021
Q3 		$0 Hold
1
– – ﹤0.01% 1003
2021
Q2 		$0 Hold
1
– – ﹤0.01% 1013
2021
Q1 		$0 Buy
+1
New +$35 ﹤0.01% 993

Other funds holding GRCE

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Sargent Bickham Lagudis's GRCE Position: Q1 2022 in Review

Sargent Bickham Lagudis sold out of Grace Therapeutics (GRCE) in Q1 2022, closing a stake of 1 share.

Sargent Bickham Lagudis first reported a position in GRCE in Q1 2021 and held it in 4 quarters. The position peaked at $0 in Q4 2021. 12 funds tracked by Wall St. Rank hold GRCE as of Q1 2022.

  • Sargent Bickham Lagudis reported no remaining Grace Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 1 Grace Therapeutics share in Q1 2022.
  • Sargent Bickham Lagudis first reported a position in Grace Therapeutics in Q1 2021 and held it in 4 quarters.
  • Sargent Bickham Lagudis's Grace Therapeutics position peaked at $0 in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2022, filed 27 Apr 2022.